Literature DB >> 18575931

Outcome analysis of blood product transfusion in trauma patients: a prospective, risk-adjusted study.

Grant V Bochicchio1, Lena Napolitano, Manjari Joshi, Kelly Bochicchio, Walter Meyer, Thomas M Scalea.   

Abstract

BACKGROUND: Studies have confirmed adverse outcome associated with transfusion of packed red blood cells (PRBCs) in trauma; however, little data are available regarding other blood product transfusion, such as fresh frozen plasma (FFP) and platelets. The objective of this study was to examine risk-adjusted outcome in trauma with stratification by blood product type.
METHODS: Prospective data were collected daily for 1,172 consecutive trauma patients admitted to the intensive care unit (ICU) during a 2-year period, including transfusion rates of blood products (PRBCs, FFP, platelets). Outcome assessment included infection rate, ventilator days (Vdays), ICU and hospital length of stay (LOS), and mortality.
RESULTS: Blood products were transfused in 786 (67%) patients. The study cohort had a mean age of 43 +/- 21 years and Injury Severity Score (ISS) of 24 +/- 13. Although the majority of patients were men, women were more likely to be transfused (p < 0.001). Mean transfusion rates of PRBCs (5.5 +/- 9.6 U), FFP (5.4 +/- 11.4), and platelets (3.7 +/- 11.1) were high. Univariate analysis identified that blood product transfusion (any type) was associated with a significantly greater infection rate (34% vs. 9.4%; p < 0.001), hospital LOS (18.6 vs. 9 days; p < 0.001), ICU LOS (13.7 vs. 7.4 days; p < 0.001), Vdays (12.9 vs. 6.3 days; p < 0.001), and mortality (19% vs. 8.3%; p < 0.001). Multivariate analysis (risk-adjusted for severity of injury by ISS, age, sex, and race, and stratified by blood product type) confirmed that risk of infection increased by 5%, and hospital LOS, ICU LOS, and Vdays increased by 0.64, 0.42, and 0.47 days, respectively, for every unit of PRBCs given. Risk of death increased by 3.5% for every unit of FFP transfused.
CONCLUSION: There is a dose-dependent correlation between blood product transfusion and adverse outcome (increased mortality and infection) in trauma patients.

Entities:  

Mesh:

Year:  2008        PMID: 18575931     DOI: 10.1007/s00268-008-9655-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  21 in total

1.  Postoperative inflammatory response after autologous and allogeneic blood transfusion.

Authors:  A Avall; M Hyllner; J P Bengtson; L Carlsson; A Bengtsson
Journal:  Anesthesiology       Date:  1997-09       Impact factor: 7.892

Review 2.  Current research on the immunomodulatory effect of allogeneic blood transfusion.

Authors:  S Dzik; M A Blajchman; N Blumberg; S A Kirkley; J M Heal; K Wood
Journal:  Vox Sang       Date:  1996       Impact factor: 2.144

3.  Blood transfusion. An independent risk factor for postinjury multiple organ failure.

Authors:  F A Moore; E E Moore; A Sauaia
Journal:  Arch Surg       Date:  1997-06

4.  Immunologic changes after transfusion of autologous or allogeneic buffy coat-poor versus white cell-reduced blood to patients undergoing arthroplasty. I. Proliferative T-cell responses and the balance of helper and suppressor T cells.

Authors:  P Innerhofer; G Luz; L Spötl; P Hobisch-Hagen; W Schobersberger; M Fischer; W Nussbaumer; A Lochs; E Irschick
Journal:  Transfusion       Date:  1999-10       Impact factor: 3.157

5.  Blood transfusion is an independent predictor of increased mortality in nonoperatively managed blunt hepatic and splenic injuries.

Authors:  William P Robinson; Jeongyoun Ahn; Arvilla Stiffler; Edmund J Rutherford; Harry Hurd; Ben L Zarzaur; Christopher C Baker; Anthony A Meyer; Preston B Rich
Journal:  J Trauma       Date:  2005-03

6.  Allogenic blood transfusion in the first 24 hours after trauma is associated with increased systemic inflammatory response syndrome (SIRS) and death.

Authors:  James R Dunne; Debra L Malone; J Kathleen Tracy; Lena M Napolitano
Journal:  Surg Infect (Larchmt)       Date:  2004       Impact factor: 2.150

7.  Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis.

Authors:  Gary E Hill; William H Frawley; Karl E Griffith; John E Forestner; Joseph P Minei
Journal:  J Trauma       Date:  2003-05

Review 8.  Transfusion of the injured patient: proceed with caution.

Authors:  Christopher C Silliman; Ernest E Moore; Jeffrey L Johnson; Ricardo J Gonzalez; Walter L Biffl
Journal:  Shock       Date:  2004-04       Impact factor: 3.454

9.  The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.

Authors:  Howard L Corwin; Andrew Gettinger; Ronald G Pearl; Mitchell P Fink; Mitchell M Levy; Edward Abraham; Neil R MacIntyre; M Michael Shabot; Mei-Sheng Duh; Marc J Shapiro
Journal:  Crit Care Med       Date:  2004-01       Impact factor: 7.598

10.  Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient.

Authors:  Robert W Taylor; Lisa Manganaro; Jacklyn O'Brien; Steven J Trottier; Nadeem Parkar; Christopher Veremakis
Journal:  Crit Care Med       Date:  2002-10       Impact factor: 7.598

View more
  24 in total

1.  Platelet transfusion increases risk for acute respiratory distress syndrome in non-massively transfused blunt trauma patients.

Authors:  George Kasotakis; Nichole Starr; Erek Nelson; Bedabrata Sarkar; Peter Ashley Burke; Daniel George Remick; Ronald Gary Tompkins
Journal:  Eur J Trauma Emerg Surg       Date:  2018-04-07       Impact factor: 3.693

2.  Abdominal and pelvic injuries caused by road traffic accidents: characteristics and outcomes in a French cohort of 2,009 casualties.

Authors:  Nicolas Cheynel; Julie Gentil; Marc Freitz; Patrick Rat; Pablo Ortega Deballon; C Bonithon Kopp
Journal:  World J Surg       Date:  2011-07       Impact factor: 3.352

3.  Fresh frozen plasma increases adhesion molecule expression on human pulmonary endothelial cells.

Authors:  Phillip A Letourneau; Shibani Pati; Michael H Gerber; Fernando Jimenez; John B Holcomb
Journal:  J Surg Res       Date:  2010-05-20       Impact factor: 2.192

4.  Persistence of elevated plasma CXCL8 concentrations following red blood cell transfusion in a trauma cohort.

Authors:  Janet S Lee; Jason L Sperry; Juan B Ochoa; Derek Barclay; Rami Namas; Yoram Vodovotz; Matthew Randall Rosengart
Journal:  Shock       Date:  2012-04       Impact factor: 3.454

5.  An audit of fresh frozen plasma usage in a tertiary trauma care centre in north India.

Authors:  Neha Agarwal; Arulselvi Subramanian; Ravindra Mohan Pandey; Venencia Albert; Sulekha Karjee; Vedanand Arya
Journal:  Indian J Hematol Blood Transfus       Date:  2013-05-15       Impact factor: 0.900

6.  Early Complications and Outcomes in Combat Injury-Related Invasive Fungal Wound Infections: A Case-Control Analysis.

Authors:  Louis R Lewandowski; Amy C Weintrob; David R Tribble; Carlos J Rodriguez; Joseph Petfield; Bradley A Lloyd; Clinton K Murray; Daniel Stinner; Deepak Aggarwal; Faraz Shaikh; Benjamin K Potter
Journal:  J Orthop Trauma       Date:  2016-03       Impact factor: 2.512

7.  Risk factors associated with invasive fungal infections in combat trauma.

Authors:  Carlos J Rodriguez; Amy C Weintrob; Jinesh Shah; Debra Malone; James R Dunne; Allison B Weisbrod; Bradley A Lloyd; Tyler E Warkentien; Clinton K Murray; Kenneth Wilkins; Faraz Shaikh; M Leigh Carson; Deepak Aggarwal; David R Tribble
Journal:  Surg Infect (Larchmt)       Date:  2014-05-12       Impact factor: 2.150

8.  Nosocomial infections after severe trauma are associated with lower apolipoproteins B and AII.

Authors:  Jon K Femling; Sonlee D West; Erik K Hauswald; Hattie D Gresham; Pamela R Hall
Journal:  J Trauma Acute Care Surg       Date:  2013-04       Impact factor: 3.313

Review 9.  Adverse effects of plasma transfusion.

Authors:  Suchitra Pandey; Girish N Vyas
Journal:  Transfusion       Date:  2012-05       Impact factor: 3.157

Review 10.  Fibrinogen metabolic responses to trauma.

Authors:  Wenjun Zhou Martini
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2009-01-13       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.